The Zeeh Pharmaceutical Experiment Station, located within the School of Pharmacy, is designed to supportthe early-stage pharmaceutical development needs of University-based and regional industry drug discoverylaboratories. The Station brings substantial industrial drug development experience to the UW NCDDGworking team, enabling it to build strategic advantage into their evolving tactical plans in meeting their longterm program goals.In the early stages of the NCDDG molecule synthesis effort, a small number of class-representativenatural product compounds will be carefully selected and used as the basis for the development of semiquantitativeanalytical methodology useful for preparation and in vitro assessment of the compounds. Forcompounds passing the initial in vitro biological activity criteria, selected representative candidates will betested for their physicochemical properties which relate to their performance in vivo, e.g. solubility and cellpermeability, to offer some guidance to the downstream testing work. In further support of in vivo studies,the Station will prepare and test (including relevant stability in vitro) formulations of approximately 16 drugcandidates selected on the basis of in vitro studies (as above) for studies of PK/metabolism in mice (permodel) at a set dose of approximately 0.5 mg/kg. In accordance with the half-lives so determined, acutetoxicology evaluation (MTD) will follow in mice (per model). From these PK/metabolism and acutetoxicology results, it is expected that 12 compounds will be chosen based on their half-life and MTD for studyin the four animal efficacy models.Station will also provide the UW NCDDG team Lab Program 3 with a coordinated administrativeinterface to the School of Pharmacy AAALAC-accredited animal facility in which mice will be housed oncethe animal models have been fully developed and will support all or a large proportion of the breedingcolonies and test animal populations for pharmacokinetics (PK) - compound half-life, dose titration;determination of MTD; acute toxicology (MTD, non-GLP); and mouse efficacy screening. The Station willalso coordinate with the Bioanalytical (GLP) laboratory in the UWCCC for the analysis of blood samplesdrawn on behalf of the PK-related studies, and will manage the data analysis.
Showing the most recent 10 out of 97 publications